Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Coagulation changes associated with the hemolytic uremic syndrome.

N Gordjani1, A H Sutor

  • 1Universitäts-Kinderklinik, University of Freiburg, Germany.

Seminars in Thrombosis and Hemostasis
|March 5, 1999
PubMed
Summary

Hemolytic uremic syndrome (HUS) involves microvascular thrombosis and organ damage. Further research into its mechanisms and treatments is crucial for improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Fetal and neonatal kidney function. Implications for fetal urinary tract abnormalities].

Aktuelle Urologie·2004
Same author

Screening children with thrombosis for thrombophilic proteins. Cui bono?

Journal of thrombosis and haemostasis : JTH·2003
Same author

Necrotizing sarcoid granulomatosis: a rarity in childhood.

Pediatric pulmonology·2003
Same author

[Catheter-related thrombosis and its prevention in infancy].

Hamostaseologie·2003
Same author

Pro- and anticoagulatory factors under sodium valproate-therapy in children.

Neuropediatrics·2002
Same author

Treatment of neuropathic bladder using botulinum toxin A in a 1-year-old child with myelomeningocele.

Pediatric nephrology (Berlin, Germany)·2002

Area of Science:

  • Nephrology
  • Hematology
  • Pathology

Background:

  • Hemolytic uremic syndrome (HUS) is a condition marked by hemolytic anemia, acute renal failure, and thrombocytopenia.
  • It is pathologically defined by thrombotic microangiopathy in renal and other organ microvasculature.
  • Endothelial cell damage is a key factor in HUS pathogenesis, leading to microvascular occlusion.

Purpose of the Study:

  • To investigate the pathophysiology of thrombotic microangiopathy in HUS.
  • To reevaluate treatment strategies for early intervention in HUS.
  • To highlight findings relevant for HUS disease management.

Main Methods:

  • Review of existing literature on HUS and thrombotic thrombocytopenic purpura (TTP).
  • Analysis of hemostatic alterations described in HUS studies.

Related Experiment Videos

  • Examination of endothelial cell damage and its role in microvascular thrombosis.

    • Main Results:

    • Platelet thrombi, without widespread coagulation activation, are characteristic of HUS and TTP.
    • Common findings include low platelet counts, elevated von Willebrand's factor (vWF), and normal fibrinogen.
    • Endothelial dysfunction contributes to the loss of fibrinolytic properties and microvascular occlusion.

    Conclusions:

    • Despite a potentially better prognosis for postdiarrheal HUS, long-term outcomes remain a concern.
    • Further investigation into HUS pathophysiology is necessary.
    • Reevaluation of therapeutic strategies targeting early thrombosis is essential.